nav1.7 inhibitor

Nav1.7 inhibitor is a Nav1.7 inhibitor for research in the field of pain and anesthesia.

NaV1.7 inhibitor-1, an efficacious inhibitor of voltage-gated sodium channel (NaV) 1.7 (IC50 of 0.6 nM for hNaV1.7).

GX 201 is a selective NaV1.7 inhibitor, IC50 of < 3.2 nM for hNaV1.7.

TC-N 1752 is an orally active inhibitor of Nav1.7 channel with IC50 of 0.17 μM. TC-N 1752 shows analgesic activities.

1-(2,4-difluorophenyl)guanidine hydrochloride is a compound that is a potent and selective inhibitor of the voltage-gated sodium channel Nav1.7, a key player in pain signaling. It is therefore able to reduce pain signaling, resulting in an analgesic effect.

GDC-0276 is an orally active, selective, and potent NaV1.7 inhibitor that can be used for the study of pain-related diseases.

GNE-0439 is a novel Nav1.7-selective inhibitor (IC50: 0.34 uM) and inhibits Nav1.5 (IC50: 38.3 μM). GNE-0439 inhibits mutant N1742K channels (IC50: 0.37 uM) in membrane potential assays.

GNE-616 is a highly potent, metabolically stable, orally bioavailable, and subtype-selective Nav1.7 inhibitor [Ki: 0.79 nM, Kd: 0.38 nM for hNav1.7] for the treatment of chronic pain.

Nav1.7-IN-6, a selective inhibitor of Nav1.7.

Nav1.7-IN-2 is avoltage-gated sodium channels (Nav) inhibitor in particular Nav 1.7(IC50 of 80 nM).

Nav1.7-IN-3 is a selective and orally bioavailable inhibitor of voltage-gated sodium channel Nav1.7(IC50 of 8 nM).

AM-2099 is a selective voltage-gated sodium channel Nav1.7 inhibitor used in pain research.

Raxatrigine hydrochloride is a state-dependent sodium channel blocker and a Nav1.7 sodium channel inhibitor.

DSP-2230 is a selective blocker of Nav1.7 Nav1.8.

Funapide (TV 45070) is a potent Sodium Channel Nav1.7 inhibitor with potential anti-inflammatory activity for the treatment of erythema gangrenosum, musculoskeletal pain, knee osteoarthritis, and postherpetic nerves.

PF-05198007 is a compound with a similar pharmacodynamic profile to PF-05089771. PF-05198007 is an effective and selective arylsulfonamide Nav1.7 inhibitor.

PF-05241328 is an effective and selective inhibitor of human Nav1.7 voltage-dependent sodium channels (IC50: 31 nM).

Nav1.7-IN-18 (Compound 31) is a Nav1.7 inhibitor with a Ki value of 4.9 nM and an IC50 of 13 nM, demonstrating analgesic effects in transgenic mice with inherited erythromelalgia (IEM).

Veratridine is a benzoate-cevane found in Veratrum and Schoenocaulon. It activates sodium channels to stay open longer than normal.

GX-395 is a novel Nav1.7 inhibitor.

GX-936, a Nav1.7 inhibitor, inhibits Nav1.7 through a voltage-sensor trapping mechanism, likely by stabilizing inactivated states of the channel.

PF-06456384 is a highly potent and selective NaV1.7 inhibitor with an IC50 value of 0.01 nM (nanomolar).

Nav1.7-IN-8 is a highly potent and selective inhibitor of NaV1.7, exhibiting greater selectivity for inhibiting NaV1.7 compared to the subtypes hNaV1.1 and hNaV1.5. Additionally, Nav1.7-IN-8 has inhibitory effects on CYP2C9 and CYP3A4, with IC50 values of 0.17 μM and 0.077 μM, respectively. Notably, Nav1.7-IN-8 demonstrates significant analgesic properties in rodent models of both acute and inflammatory pain.

Neoline is an active ingredient of A. venetum root (PA) that ameliorates oxaliplatin-induced peripheral neuropathy in mice.Neoline inhibits Nav1.7 voltage-gated sodium channel currents (VGSC). It can be used as a labeling compound to determine the quality of PA products used in the study of neuropathic pain.